Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.74 |
| ▸ | CTSK | P43235 | 5/20 | 0.68 |
| ▸ | CTSL | P07711 | 5/20 | 0.67 |
| ▸ | CTSB | P07858 | 4/20 | 0.67 |
| ▸ | MME | P08473 | 1/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21219352 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL21219280 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL29483597 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL9831181 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL21219351 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL931659 | 0.95 | CAPN1 (0.69) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL27809377 | 0.95 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBHTRA1 | |
| SCHEMBL9828791 | 0.95 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBHTRA1 | |
| SCHEMBL7327426 | 0.95 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBHTRA1 | |
| SCHEMBL25406813 | 0.94 | CTSK (0.77) | CAPN1CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-12577570-B2 | Modified neuraminidase | TOKUSHIMA UNIVERSITY (JP) | 2026-03-17 | — | — | US | disclosed |
| CN-118685385-A | Carboxypeptidase A mutant with improved acid stability and soluble expression quantity | 中国农业大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-117737043-A | Carboxypeptidase A mutant with improved thermostability and activity | 中国农业大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-116981681-A | Compounds for the treatment of segmental premature senility syndrome | 普罗基莱弗公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-110724682-B | Method for preparing immobilized enzyme from zeolitic imidazolate framework compound | 江苏科技大学 | 2022-12-27 | — | — | CN | disclosed |
| US-20220364101-A1 | MODIFIED NEURAMINIDASE | TOKUSHIMA UNIVERSITY (JP) | 2022-11-17 | — | — | US | disclosed |
| CN-114555800-A | Modified neuraminidase | 国立大学法人德岛大学 | 2022-05-27 | — | — | CN | disclosed |
| EP-4000637-A1 | MODIFIED NEURAMINIDASE | Tokushima University (JP) | 2022-05-25 | — | — | EP | disclosed |
| WO-2008028000-A2 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| US-4587234-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4560506-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-12-24 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577570-B2 | Modified neuraminidase | CTSS, CTSD, CTSV | CAPN1 235/4885CTSK 16/4885CTSL 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.